Macroaxis: Personalized Investing
Personalized Investing and
Digital Wealth Optimization

GILD AMGN CELG BIIB 
Benchmark  United States  NYSE  11,029   12.043 Index Moved Down -0.11%  


Processing
Collecting data for STEM

StemCells Inc StemCells Inc

   
$1.14
Change0.021.72%
Year To Date
1.022.43
Last 1 Month(s)
1.11.27
Trading Day 
1.131.17
5 Days Price Trend
November 26, 2014 
Highest Price  
Lowest Price  
November 17, 2014 
November 10, 2014 

StemCells Market Sensitivity

As returns on market increase, returns on owning StemCells are expected to decrease at a much smaller rate. During bear market, StemCells is likely to outperform the market.
StemCells Inc Almost negative betaStemCells Inc Beta Legend
STEM
StemCells Inc
USA Stock
Healthcare
Biotechnology
Benchmark NYSE
http://www.stemcellsinc.com
Contact Number: 510. 456. 4000
Currency: USD - US Dollar
Traded on Nasdaq Capital Markets
 
Current Valuation80.89 M
Shares Outstanding68.64 M
Number of Shares Shorted3.81 M
Revenue1.22 M
 United States Nasdaq   0.07 % Macroaxis: 0.07 Moved Up  
 
 United States Russel   0.05 % Macroaxis: 0.05 Moved Down  
 
 United States NYSE   0.11 % Macroaxis: 0.11 Moved Down  
 
 United States SP 500   0.12 % Macroaxis: 0.12 Moved Down  
 
 thisRed STEM STEM agains markets  1.72 % Macroaxis: change 1.72 Moved Down  
 
Compare to Competition   Compare Correlations

StemCells Leadership

Martin McGlynn CEO and President Director, Member of Strategic Transactions Committee, CEO of StemCells California Inc and President of StemCells California Inc
John Schwartz Independent Chairman of the Board, Ph.D

StemCells Diversification Suggestion

Use StemCells to protect against small markets fluctuations. The stock experiences somewhat bearish sentiment, but market may correct it shortly. Check odds of StemCells to be traded at $1.1058 in 30 days

StemCells Price and Market Media

The median price of StemCells for the period between Mon, Oct 27, 2014 and Wed, Nov 26, 2014 is 1.2 with a coefficient of variation of 3.35. The daily time series for the period is distributed with a sample standard deviation of 0.04, arithmetic mean of 1.19, and mean deviation of 0.03. The Stock received some media coverage during the period.
StemCells Value
 
Change Benchmark  Embed   Timeline 

StemCells Summary

StemCells Inc [STEM] is traded on Nasdaq Capital Markets in USA. It is located in Newark, CA and employs 58 people. The company currently falls under 'Micro-Cap' category with current market capitalization of 83.74 M. StemCells Inc conducts business under Healthcare sector and is part of Biotechnology industry. This company has 68.64 M outstanding shares of which 3.81 M shares are at this time shorted by private and institutional investors with about 5.0 trading days to cover.
StemCells, Inc., a biopharmaceutical company, is engaged in the research, development, and commercialization of stem cell therapeutics, and related tools and technologies for stem cellbased research and drug discovery and development. more
Over 30
Days
0
Out Of
100
 
More
Than
96
%
 
Hyped down

StemCells Alerts

StemCells Inc generates negative expected return over the last 30 days
StemCells Inc may become a speculative penny stock
StemCells Inc has high likelihood to experience some financial distress in the next 2 years
The company reported previous year revenue of 1.22 M. Net Loss for the year was (33.89 M) with profit before overhead, payroll, taxes, and interest of 886.64 K.
STEMCELLS INC currently holds about 17.85 M in cash with (27.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.26.
Roughly 24.0% of the company outstanding shares are owned by corporate insiders
StemCells Inc. to Host Inaugural Investor and Analyst Event in New York

StemCells Earnings Estimates

StemCells Inc normalized analysts earnings estimates over time
  

StemCells Research Report

Get StemCells research report. Reports are available in pdf format. Click Generate Report to view
  
Generate Report  

StemCells Pair Trading Analysis

Correlation analysis and pair trading evaluation for StemCells and Gilead Sciences
  

Explore Investment Opportunities

Investing ideals could easily outperform a given market if properly optimized

StemCells Directors

Irving Weissman Director
Eric Bjerkholt Independent Director
R Greer Independent Director
Ricardo Levy Independent Director
Alan Trounson Director

StemCells Fundamentals

StemCells vs Competition

StemCells November 26, 2014 Opportunity Range


 

Analytics

Risk Adjusted Returns Landscape
Live Efficient Frontier
Market Correlation Analysis
Watchlist Analysis
Financial Content
Portfolio Estimation and Projections
Portfolio Theme Builder
 
 

Research Modules

Equities Backtesting Analysis
Instant Retirement Optimizer
Cross-portfolio RSS and Mobile Access
Company, fund, and ETF Directory
Financial Advisor Directory
Insider and Manager Directory
Wealth Management
 

Services And Technology

Frequently Asked Questions
Quick Product Tour
Product Technology Overview
Solution Methodology
Plans and Pricing
 

Free Investor Tools

World Market Correlations
Instant Equity Comparator
Watchlist Analysis
Position Suggestions
Equity Alpha Analysis
 

About Us

About Macroaxis
Contact Us
Product Terms Of Use
Service Privacy Policy
Advertising Opportunities